<DOC>
	<DOCNO>NCT00433069</DOCNO>
	<brief_summary>The aim study investigate efficacy safety insulin-sensitizer ( Actos ) add standard Pegasys/Copegus combination therapy chronic hepatitis C patient previously fail pegylated-interferon-alpha / ribavirin combination without insulin sensitizer . The primary endpoint initial virological response ( level HCV RNA serum ) evaluate 12 week triple therapy .</brief_summary>
	<brief_title>Retreatment Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone</brief_title>
	<detailed_description>Insulin resistance diabetes major disease modifier chronic hepatitis C , increase liver fibrogenesis reduce rate response antiviral . Regarding latter , previous study show sustained virological response ( SVR ) occur one third patient genotype 1 insulin resistance ( measure homeostasis assessment insulin resistance , HOMA-IR &gt; 2 ) vs. two third genotype 1 patient without insulin resistance . These finding independently confirm study extend non-responders genotype 2 , 3 4 . Thus , suggest insulin resistance correct patient chronic hepatitis C respond currently available antiviral treatment , order improve response retreatment . The modality intervention , however , establish . In addition , optimal HOMA-IR score attain identify . To assess point , plan prospective , multicenter study investigate efficacy safety insulin-sensitizer pioglitazone ( ActosTM , Takeda Pharma AG , Lachen , Switzerland ) 15 mg QD , add pegylated interferon-α2a ( PEG-IFN-α2a ) ( PegasysTM , Roche Pharma Schweiz AG , Reinach , Switzerland ) 180 μg QW/ribavirin ( CopegusTM , Roche ) 1000-1200 mg QD combination therapy chronic hepatitis C patient previously fail respond ( i.e . detectable serum HCV RNA 12 week therapy ) pegylated interferon-α/ribavirin combination without insulin-sensitizer . All patient baseline HOMA-IR score &gt; 2 additional inclusion criterion , threshold discriminate responder non-responders previous work . Diabetic patient exclude .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Histologically confirm chronic hepatitis C per liver biopsy perform 12 month prior enrollment ( except patient histologically proven cirrhosis Actitest/Fibrotest assay , Fibroscan perform 12 month prior enrollment ) HCV RNA serum &gt; 600 IU/ml elevate ALT HCV genotypes 1 , 2 , 3 4 failure respond prior treatment pegylated interferon alpha + ribavirin HOMA score &gt; 2.00 documentation sexually active female patient childbearing potential practicing adequate contraception ( intrauterine device , oral contraceptive , progesterone implant rod , medroxyprogesterone acetate , surgical sterilization plus barrier method [ diaphragm + spermicide ] monogamous relationship male partner vasectomy use condom + spermicide ) treatment period 6 month discontinuation therapy . A serum pregnancy test obtain entry prior initiation treatment must negative . Female patient must breast feeding documentation sexually active male patient practice acceptable method contraception ( vasectomy , use condom + spermicide , monogamous relationship female partner practice acceptable method contraception ) treatment period 6 month discontinuation therapy willingness capability give write informed consent comply requirement trial history diabetes ( ADA definition ) history significant cardiovascular disease ( NYHA III ) include limit uncontrolled hypertension , angina pectoris , myocardial infarction , coronary artery surgery congestive heart failure HBsAg and/or HIV autoimmune disease , include autoimmune hepatitis alcohol consumption exceed 40 gram per day hepatocellular carcinoma renal insufficiency ( serum creatinine level 200 micromol/l ) unconjugated bilirubin blood level &gt; 100 micromol/l glutamyl transferase &gt; 20 time ULN prothrombin time &lt; 60 % control ( except case oral anticoagulant therapy ) neutrophil count &lt; 1.5 G/L platelet count &lt; 70 G/L hemoglobin &lt; 120 g/L organ bone marrow transplantation current neoplasm and/or antitumor chemotherapy current hepatic arterial thrombosis pregnant breast feeding woman ; child bear potential woman without adequate contraception throughout course therapy psychosis antidepressant therapy uncontrolled clinical depression epilepsy clinically significant retinal abnormality thyroid dysfunction drug abuse substitution therapy 12 month prior inclusion interstitial pneumonitis previous autoimmune hemolysis cause chronic hemolysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Non-responders</keyword>
</DOC>